scholarly journals Axillary lymphadenopathy in a high-risk breast screening patient following the COVID-19 vaccine: a diagnostic conundrum

2021 ◽  
pp. 20210063
Author(s):  
Besma Musaddaq ◽  
Adam Brown ◽  
Sam Dluzewski ◽  
Teresa Marafioti ◽  
Anmol Malhotra
Keyword(s):  
High Risk ◽  
Metastatic Disease ◽  
Side Effect ◽  
Breast Screening ◽  
Axillary Lymphadenopathy ◽  
Brca Carrier ◽  
High Risk Breast

A number of COVID-19 vaccines have been approved worldwide to help tackle the pandemic. As with many vaccines, this causes a reactive axillary lymphadenopathy which can mimic potentially metastatic disease in a breast screening patient. It is therefore important to be aware of this side-effect of the vaccination when evaluating the axilla in a breast screening patient. We present a case of biopsy proven unilateral reactive axillary lymphadenopathy in a high risk BRCA carrier following administration of the Astra Zeneca vaccine.

scholarly journals Evaluation of breast screening strategies in a high risk breast and ovarian cancer clinic

2020 ◽  
Vol 33 ◽  
pp. 100587
Author(s):  
Anne T. Knisely ◽  
Martha E. Stewart ◽  
Christine Garcia ◽  
Martha H. Thomas ◽  
Susan C. Modesitt ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Risk ◽  
Breast Screening ◽  
Breast And Ovarian Cancer ◽  
Screening Strategies ◽  
High Risk Breast ◽  
Cancer Clinic

scholarly journals NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program

Cancers ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 707 ◽  
Author(s):  
Nika Maani ◽  
Shelley Westergard ◽  
Joanna Yang ◽  
Anabel M. Scaranelo ◽  
Stephanie Telesca ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Breast Cancer Screening ◽  
Breast Screening ◽  
Screening Program ◽  
Type I ◽  
Screening Programs ◽  
Increased Risk ◽  
High Risk Breast

Neurofibromatosis Type I (NF1) is caused by variants in neurofibromin (NF1). NF1 predisposes to a variety of benign and malignant tumor types, including breast cancer. Women with NF1 <50 years of age possess an up to five-fold increased risk of developing breast cancer compared with the general population. Impaired emotional functioning is reported as a comorbidity that may influence the participation of NF1 patients in regular clinical surveillance despite their increased risk of breast and other cancers. Despite emphasis on breast cancer surveillance in women with NF1, the uptake and feasibility of high-risk screening programs in this population remains unclear. A retrospective chart review between 2014–2018 of female NF1 patients seen at the Elizabeth Raab Neurofibromatosis Clinic (ERNC) in Ontario was conducted to examine the uptake of high-risk breast cancer screening, radiologic findings, and breast cancer characteristics. 61 women with pathogenic variants in NF1 enrolled in the high-risk Ontario breast screening program (HR-OBSP); 95% completed at least one high-risk breast screening modality, and four were diagnosed with invasive breast cancer. Our findings support the integration of a formal breast screening programs in clinical management of NF1 patients.

Improvement in DCIS Detection Rates by MRI Over Time in a High-Risk Breast Screening Study

2011 ◽  
Vol 17 (1) ◽  
pp. 9-17 ◽  
Author(s):  
Ellen Warner ◽  
Petrina A. Causer ◽  
John W-N. Wong ◽  
Frances C. Wright ◽  
Roberta A. Jong ◽  
...  
Keyword(s):  
High Risk ◽  
Breast Screening ◽  
Detection Rates ◽  
Screening Study ◽  
High Risk Breast ◽  
Over Time
Sign in / Sign up

Export Citation Format

Share Document